10333 results for 'part delta next'

An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci

Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics

For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, high

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form

Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th

Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th

Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An

For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel

Department of Oncology RetreatAssay Genie was honoured to sponsor and participate in the inaugural 2025 Department of Oncology Retreat, hosted by the University of Lausanne and Lausanne

Interferons (IFNs) are a group of signalling proteins that are produced and released from cells in response to viral infection and other stimuli such as normal and tumour cell survival and

Notch signalling pathway review The Notch signalling pathway is a highly conserved intercellular signalling pathway that regulates various cellular processes. The Notch receptor is a transmem

Immunology · Flow CytometryT Cell Immunophenotyping: Markers, Subsets and Panel DesignImmunophenotyping identifies cell populations by the proteins on their surface. For T cells that means resolving n

We know it gets tiring being in the lab every day, especially with the evenings getting darker and gloomier. So, to get you in the festive spirit, we're holding a competition to win money to th

A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a

The Notch signaling pathway is a highly conserved cellular communication system that plays a crucial role in various biological processes, including embryonic development, tissue homeostasis, a